Ramakrishnan TCR, et al. - Researchers assessed the efficacy and safety of tenecteplase (TNK-tPA, a promising third-generation plasminogen activator with longer half-life than alteplase), compared with that of alteplase, in two studies ie, an open-label, randomized study in which two doses of TNK-tPA (0.1 and 0.2 mg/kg) were compared (Study I) and an open-label study in which TNK-tPA 0.2 mg/kg bolus was compared with historical controls (Study II). Findings revealed that, seemingly, patients with acute ischemic stroke well tolerated intravenous TNK-tPA 0.2 mg/kg administered within 3 hours of symptom onset and it affords an effective option for these patients.